What Is Peptide Therapy

Peptide therapy involves the clinical use of short chains of amino acids, typically between 2 and 50 residues, that function as signaling molecules in the body. These peptides can influence hormone secretion, immune activity, tissue repair, and inflammation by binding to specific cell-surface receptors. The approach spans a wide range of compounds, each targeting distinct biological pathways.

Aging involves a progressive decline in the signaling molecules that coordinate repair, immune surveillance, and metabolic regulation. Many endogenous peptides, including growth hormone-releasing peptides and thymic peptides, decrease in production or effectiveness with age. Supplementing or mimicking these signals is the rationale behind peptide therapy's application in longevity medicine.

The relevance to healthspan is direct: peptides that stimulate growth hormone secretion may help preserve lean mass and bone density, while immune-modulating peptides may help sustain the body's defense capacity. Tissue-repair peptides address the slower wound healing and connective tissue degradation that characterize biological aging. Because peptides tend to work through the body's existing receptor systems rather than overriding them, advocates argue they carry a different risk profile than direct hormone replacement, though this claim requires more long-term data to evaluate fully.

Peptides function by binding to specific receptors on cell surfaces, triggering intracellular signaling cascades. Growth hormone secretagogue peptides such as ipamorelin and CJC-1295 bind to the growth hormone secretagogue receptor (GHSR) or the growth hormone-releasing hormone receptor (GHRHR) on pituitary somatotroph cells. This binding stimulates pulsatile release of endogenous growth hormone, which in turn drives IGF-1 production in the liver. The result is an amplification of the body's own anabolic and repair signaling rather than an exogenous replacement.

Tissue-repair peptides operate through different mechanisms. BPC-157, a synthetic fragment derived from a gastric protein, appears to upregulate growth factor receptors, promote angiogenesis, and modulate nitric oxide pathways in animal models. Thymosin Beta-4 (TB-500) binds to actin monomers and influences cell migration and differentiation, processes central to wound healing. GHK-Cu, a copper-binding tripeptide, activates genes involved in collagen synthesis, antioxidant defense, and DNA repair.

Immune-modulating peptides such as Thymosin Alpha-1 mimic natural thymic peptides that decline with thymic involution during aging. These peptides influence T-cell maturation, dendritic cell function, and cytokine balance. By engaging toll-like receptors and other immune regulatory pathways, they can shift immune activity toward more effective pathogen clearance and away from chronic inflammatory states. The specificity of each peptide's receptor interaction is what allows clinicians to select compounds for targeted physiological effects.

An initial consultation typically involves a detailed health history, discussion of goals, and baseline bloodwork including IGF-1, metabolic markers, and inflammatory panels. The clinician selects one or more peptides based on the clinical picture and prescribes them through a compounding pharmacy. Patients receive instruction on reconstituting lyophilized peptides (if applicable), proper injection technique for subcutaneous administration, and storage requirements, since most peptides require refrigeration after reconstitution.

Onset of noticeable effects varies by peptide and goal. Sleep quality improvements from growth hormone secretagogues are sometimes reported within the first week. Changes in body composition, recovery speed, or joint comfort typically take four to eight weeks to become apparent. Follow-up labs are usually drawn at the midpoint or conclusion of a cycle to assess biomarker changes and guide protocol adjustments.

Dosing frequency depends on the peptide. Growth hormone secretagogues like ipamorelin are commonly injected once daily, typically before bed. BPC-157 is often dosed once or twice daily, sometimes locally near the site of injury. Thymosin Alpha-1 may be administered two to three times per week.

Protocols are usually structured in cycles rather than continuous indefinite use. A standard cycle runs 8 to 12 weeks, followed by a washout period of several weeks before reassessment. Some clinicians prescribe maintenance phases at reduced frequency after an initial loading period. The cycling approach is intended to prevent receptor desensitization and to allow periodic reassessment of whether continued therapy is warranted.

Peptide therapy costs vary based on the specific peptide, dosage, source pharmacy, and whether clinical supervision is included. A single peptide from a reputable compounding pharmacy typically costs between $100 and $400 per month of supply. The initial clinical consultation, which often includes comprehensive bloodwork, may range from $250 to $600 depending on the provider and the extent of testing ordered. Follow-up visits and repeat labs add to the total investment.

Insurance rarely covers peptide therapy when used for longevity or performance optimization, as most applications fall outside approved indications. Some concierge or functional medicine practices bundle peptide protocols into membership fees, which can range from $200 to $500 per month. The total cost for a full 8 to 12 week cycle, including consultation, labs, and peptide supply, commonly falls between $500 and $2,000.

The evidence base for peptide therapy varies dramatically by compound. A few peptides have been studied in randomized controlled trials for specific medical indications: tesamorelin has robust clinical trial data for reducing visceral fat in HIV-associated lipodystrophy, and Thymosin Alpha-1 has been evaluated in trials for hepatitis and as an immunotherapy adjunct. Growth hormone secretagogues such as ipamorelin and CJC-1295 have human pharmacokinetic and safety data from early-phase trials, but large-scale efficacy trials for longevity-specific outcomes are absent.

BPC-157, one of the most widely discussed peptides in regenerative medicine, has an extensive body of animal research demonstrating effects on tendon healing, gut mucosal repair, and neuroprotection. However, published human trial data for BPC-157 remains extremely limited. TB-500 and GHK-Cu similarly rely primarily on preclinical and in vitro evidence. The gap between animal findings and confirmed human outcomes is a recurring theme across the peptide therapy landscape. Compounding this uncertainty, many peptides used clinically are obtained from compounding pharmacies with variable quality standards, making it difficult to compare results across practitioners or to generalize from individual clinical experience.

Side effects depend on the specific peptide but can include injection site irritation, water retention, tingling or numbness, increased hunger, and transient changes in blood glucose. Growth hormone secretagogues carry theoretical concerns about long-term stimulation of the GH/IGF-1 axis, which has complex and context-dependent relationships with cancer risk. Purity and dosing accuracy from compounding pharmacies are not guaranteed to the same standard as FDA-approved pharmaceuticals, and contamination or degradation during shipping and storage can affect both safety and efficacy. The FDA has moved to restrict compounding of certain peptides, making regulatory status an evolving consideration. Individuals with active malignancies or a history of hormone-sensitive cancers should approach growth-promoting peptides with particular caution, and any peptide protocol should be supervised by a qualified clinician.